论文部分内容阅读
目的:观察膀胱粘膜下注射丝裂霉素 C预防膀胱癌术后复发的临床疗效。方法:85 例膀胱癌患者随机分为两组:(1)粘膜下注药组43 例,在肿瘤切除后术中应用丝裂霉素 C6~8 m g 加生理盐水40~60 m L行膀胱粘膜下注射。(2)对照组42 例,术后应用丝裂霉素 C20 m g 加生理盐水40 m L定期膀胱内灌注。观察两组肿瘤复发情况。结果:经随访12~66 个月,平均38 个月,粘膜下注药组肿瘤复发率为9.3% ,膀胱内灌注组为30.9% ,两组比较,差异有显著性( P<0.05)。粘膜下注射丝裂霉素 C未见明显的副作用。结论:膀胱粘膜下注射丝裂霉素 C能更有效地预防膀胱癌的术后复发,具有操作简单,安全,副作用少,费用低等优点。
Objective: To observe the clinical efficacy of intravesical instillation of mitomycin C in the prevention of postoperative recurrence of bladder cancer. Methods: Eighty-five patients with bladder cancer were randomly divided into two groups: (1) 43 patients under submucosal injection group were given intravesical instillation of mitomycin C6-8 mG plus normal saline 40-60 mL Submucosal injection. (2) In the control group, 42 cases were given intravesical instillation of intravesical instillation of mitomycin C20 m g plus normal saline 40 m L after operation. Tumor recurrence was observed in both groups. Results: After a follow-up of 12 to 66 months, with an average of 38 months, the tumor recurrence rate was 9.3% in submucosal injection group and 30.9% in intravesical instillation group. There was significant difference between the two groups (P < 0.05). Submucosal injection of mitomycin C no obvious side effects. Conclusion: Injecting mitomycin C into bladder mucosa can effectively prevent postoperative recurrence of bladder cancer, which has the advantages of simple operation, safety, less side effects and low cost.